OBJECTIVE: Both conventional and second-generation antipsychotics have been associated with an increased risk for impaired glucose tolerance and diabetes mellitus. Though this has been largely attributed to weight gain, there may also be a direct, receptor-mediated effect of antipsychotics on glucose tolerance. We tested the hypothesis that antagonism of the serotonin (5-HT)-2 receptor impairs insulin sensitivity. METHODS:Ten healthy male volunteers were included in a double-blind, placebo-controlled crossover study of a single dose of 40 mg of the 5-HT2 antagonist ketanserin versus placebo. Insulin sensitivity was measured by means of the euglycemic-hyperinsulinemic clamp technique. Subjects were treated with the alpha-1 adrenergic antagonist phenoxybenzamine in both parts of the study to control for ketanserin's effects at the level of this receptor. RESULTS: Compared with the placebo condition, subjects showed a significantly decreased insulin sensitivity after ketanserin (placebo: 9.4 +/- 3.6 mg/kg/min; ketanserin: 7.7 +/- 2.1 mg/kg/min; p = .047). CONCLUSION: The selective 5-HT2 antagonist ketanserin impaired insulin sensitivity. This effect was possibly mediated by suppression of 5-HT(2A) receptor mediated glucose uptake in skeletal muscle.
RCT Entities:
OBJECTIVE: Both conventional and second-generation antipsychotics have been associated with an increased risk for impaired glucose tolerance and diabetes mellitus. Though this has been largely attributed to weight gain, there may also be a direct, receptor-mediated effect of antipsychotics on glucose tolerance. We tested the hypothesis that antagonism of the serotonin (5-HT)-2 receptor impairs insulin sensitivity. METHODS: Ten healthy male volunteers were included in a double-blind, placebo-controlled crossover study of a single dose of 40 mg of the 5-HT2 antagonist ketanserin versus placebo. Insulin sensitivity was measured by means of the euglycemic-hyperinsulinemic clamp technique. Subjects were treated with the alpha-1 adrenergic antagonist phenoxybenzamine in both parts of the study to control for ketanserin's effects at the level of this receptor. RESULTS: Compared with the placebo condition, subjects showed a significantly decreased insulin sensitivity after ketanserin (placebo: 9.4 +/- 3.6 mg/kg/min; ketanserin: 7.7 +/- 2.1 mg/kg/min; p = .047). CONCLUSION: The selective 5-HT2 antagonist ketanserinimpaired insulin sensitivity. This effect was possibly mediated by suppression of 5-HT(2A) receptor mediated glucose uptake in skeletal muscle.
Authors: Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler Journal: Wien Klin Wochenschr Date: 2006-05 Impact factor: 1.704
Authors: Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu Journal: Acta Pharmacol Sin Date: 2014-06 Impact factor: 6.150
Authors: Yvette E Savoy; Michael A Ashton; Matthew W Miller; Frank M Nedza; Douglas K Spracklin; Mark H Hawthorn; Hans Rollema; F Fatima Matos; Eva Hajos-Korcsok Journal: Schizophr Bull Date: 2008-08-14 Impact factor: 9.306
Authors: Julie Wagner; Nancy A Allen; Leah M Swalley; Gail D Melkus; Robin Whittemore Journal: Diabetes Res Clin Pract Date: 2009-08-31 Impact factor: 5.602
Authors: Daniel Duerschmied; Ingo Ahrens; Maximilian Mauler; Christoph Brandt; Stefanie Weidner; Christoph Bode; Martin Moser Journal: PLoS One Date: 2012-02-27 Impact factor: 3.240